GRIN Therapeutics Inc.

The number of venture capital mega-rounds raised by biopharmaceutical companies has settled into a steady pace of six $100m-plus financings per month, with May matching the number of supersized VC rou

Angelini Pharma of Italy, which is hoping to become the leading brain health drugmaker in the sector, is buying a stake in GRIN Therapeutics and securing the international rights to the US biotech’s n

MEM-ANT3310, which Antabio is developing to address antimicrobial resistance (AMR) in severe hospital infections, is among the latest products to secure a place on PRIME, the European Medicines Agency